
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is positioned favorably in the oncology market with its clinical-stage development of stenoparib, an innovative therapy demonstrating median overall survival exceeding 25 months for patients with advanced recurrent ovarian cancer. The company's valuation appears attractive, supported by positive net present value (NPV) analyses indicating significant upside potential from the current share price. Furthermore, the proprietary Drug Response Predictor (DRP) technology enables refined patient selection, which may enhance clinical outcomes and further solidify the company's market position in the highly competitive pharmaceutical landscape.
Bears say
Allarity Therapeutics Inc. reported a net loss of $2.8 million, with an earnings per share (EPS) of $(0.19), which was slightly better than the estimated EPS of $(0.23), yet still indicates ongoing financial challenges. The company's financial health is further compromised by significant risks, including liquidity issues, potential failures in clinical trials, and the ability to secure necessary regulatory approvals for its lead candidate, stenoparib. Additionally, macroeconomic factors and changing investor sentiment towards biotech stocks add to the uncertainties, leading to a cautious outlook on the company's future performance.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares